Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Everolimus is an mTOR inhibitor, a close relative of sirolimus: it blocks mTOR, a protein that controls cell growth, division and blood vessel formation. At higher doses it is a targeted cancer medicine for advanced breast, kidney and neuroendocrine cancers and for tumours in tuberous sclerosis; at lower doses it prevents rejection after kidney and liver transplants. It is sold as Afinitor and Zortress, among other names.
Everolimus is broken down mainly by CYP3A4, with help from CYP3A5 and CYP2C8, and pumped out of cells by ABCB1. Studies have looked at these genes for its blood levels in transplant patients, and at genes of the mTOR pathway (MTOR, RPTOR, PIK3R1) for response and side effects in cancer. The findings come from single or a few studies, and there is no CPIC or DPWG guideline.
Every published finding on gene variants and Everolimus. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
CYP3A5 CYP3A5*1, CYP3A5*3: Level 3. Metabolism/PK: Breast Neoplasms, Heart transplantation, Kidney Neoplasms, Kidney Transplantation, Lung transplantation, Neuroendocrine Tumors. 6.
PIK3R1 rs10515074: Level 3. Toxicity: Breast Neoplasms, Hyperglycemia, Leukopenia. 1.
MTOR rs2024627: Level 3. Efficacy: Breast Neoplasms, Kidney Neoplasms, Neuroendocrine Tumors. 1.
FGFR4 rs351855: Level 3. Efficacy: Discontinuation. 1.
Studies of how quickly the body processes this medication.
Studies of how much of the drug people needed or tolerated.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com